GlassScriptPhysician profile
Srijoy Mahapatra
NPI 1295715282
$1,188,673.19
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $265K · 2021: $72K · 2022: $625K · 2023: $124K · 2024: $84K · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $208K · Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $207,541.44 |
| Food and Beverage | $197.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $818,740.05 | 2021-2024 | |
| Atricure, INC. | $271,170.17 | 2019-2024 | |
| Abbott Laboratories | $98,092.64 | 2019-2023 | Mitraclip |
| Acutus Medical, INC. | $193.17 | 2021 | |
| Biotronik INC. | $134.69 | 2019 | |
| Pulse Biosciences, INC. | $126.57 | 2025 | Cellfx |
| Boston Scientific Corporation | $99.14 | 2022 | |
| Abiomed | $60.93 | 2021 | |
| Kci USA, INC. | $35.57 | 2022 | |
| Medtronic Vascular, INC. | $20.26 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,489,243.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srijoy Mahapatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.